Infections in children following chimeric antigen receptor T‐cell therapy for B‐cell acute lymphoblastic leukemia

Abstract

BackgroundCD19‐directed chimeric antigen receptor T‐cell (CAR‐T) therapy is transforming care for pediatric patients with relapsed or refractory B‐cell acute lymphoblastic leukemia (B‐ALL). There are limited pediatric‐specific data concerning the infection risks associated with CD19 CAR‐T therapy and the adequacy of current antimicrobial prophylaxis guidelines for these patients.MethodsWe describe the antimicrobial prophylaxis used and the types of infectious occurring in the first 100 days following CAR‐T therapy for relapsed or refractory B‐cell ALL in children and adolescents (≤18 years) at our centre.ResultsTwenty‐seven patients received their first CAR‐T infusion (CTI) during the study period. Almost all patients (96%) had a comprehensive Infectious Diseases review prior to CTI, which informed a personalised prophylaxis or fever/sepsis plan in six (22%). Overall, six (22%) patients had one or more infections during the study period including five (19%, 0.9 per 100 days‐at‐risk) from days 0–30 and three (n = 20, 15%, 0.6 per 100 days‐at‐risk) from days 31–100. Bacterial blood stream infections were the most common type of infection encountered during both time periods, and one patient had probable pulmonary aspergillosis. There were no infection‐related deaths.ConclusionOur study contributes important information on the spectrum of infections encountered in pediatric patients with B‐ALL post CAR‐T therapy. Overall, the burden of infectious complications post CAR‐T therapy in our cohort is lower than previously reported in the literature. Results suggest that our prophylaxis recommendations are effective in this population.